A comparative evaluation of antimicrobial eye drops cytotoxicity

Abstract

In addition to the spectrum of antibacterial activity of antimicrobial medicines and their pharmacokinetic and pharmacodynamic properties, their safety is also an important issue. Currently, there is no consensus on the fluoroquinolone toxicity. The purpose of this study was to compare in vitro the overall cytotoxic effect of six antibacterial fluoroquinolone eye drops: 1. Cipromed™ (ciprofloxacin 0.3 %; Sentiss Pharma Pvt. Ltd., India); 2. Floxal™ (ofloxacin 0.3 %; Dr. Gerhard Mann, Chem.-Pharm. Fabrik GmbH, Germany); 3. Oftaquix™ (levofloxacin 0.5 %; Santen Oy, Finland); 4. Signicef® (levofloxacin 0.5 %; Sentiss Pharma Pvt. Ltd., India); 5. Vigamox® (moxifloxacin 0.5 %; Alcon Laboratories, Inc., USA); 6. Zymar® (gatifloxacin 0.3 %; Allergan Sales LLC, USA). The study showed the possibility of using cultured cells for comparative evaluation of cytotoxic effects of various ophthalmic preparations. We found that tested antimicrobial medicines may have a cytostatic effect in vitro and differ in their cytotoxic potential.

Keywords

cytitoxicity / fluoroquinolones / eye drops

References

[1] Еропкин М. Ю., Еропкина Е. М. Культуры клеток как модельная система исследования токсичности и скрининга цитопротекторных препаратов. СПб.: Морсар АВ; 2003.

[2] Данченко Е. О. Оценка цитотоксичности фармацевтических субстанций с использованием клеточных культур. Иммунопатология, аллергология, инфектология. 2012; 2: 22-31.

[3] Курляндский Б. А., Филатов В. А. Общая токсикология. М.: Медицина; 2002.

[4] Околов И.Н, Поляк М. С. Моксифлоксацин как средство профилактики и лечения инфекции глаз. Новое в офтальмологии. 2011; 3: 64-71.

[5] Романова С. Г., Серебренникова Г. А., Штиль А. А. Синтез, изучение цитотоксических свойств и гемолитической активности катионных глицеролипидов алкильного типа. Вестник МИТХТ. 2008; 3 (5): 101-5.

[6] Ayaki M., Iwasawa A., Soda M. et al. Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines. Clinical Ophthalmology. 2010; 4:1019-24.

[7] Ayaki M., Iwasawa A., Niwano Y. In vitro assessment of the cytotoxicity of six topical antibiotics to four cultured ocular surface cell lines. Biocontrol Sci. 2012: Jun; 17 (2): 93-9.

[8] Bezwada P., Clark L., Schneider S. Intrinsic cytotoxic effects of fluoroquinolones on human corneal keratocytes and endothelial cells. Current Medical Research and Opinion. 2008; 24: 1-6.

[9] Cutarelli P., Lass J., Lazarus H. et al. Topical fluoroquinolones: antimicrobial activity and in vitro corneal epithelial toxicity. Curr Eye Res. 1991: Jun; 10 (6): 557-63.

[10] Dart J. Corneal toxicity: the epithelium and stroma in iatrogenic andfactitious disease. Eye. 2003; 17: 886-92.

[11] Han K., Chung W., Kim T. et al. Epithelial wound healing after cataract surgery comparing two different topical fluoroquinolones. Yonsei Med J. 2014; 55 (1): 197-202.

[12] Kaji Y., Oshika T. Fluoroquinolone Toxicities to Corneal Endothelial Cells. Atarashii Ganka. Journal of the Eye. 2007; 24 (9): 1229-32.

[13] Kim S., Lim J., Choi J. et al. Comparison of antibiotic effect and corneal epithelial toxicity between levofloxacin and moxifloxacin in vitro.Cornea. 2007; 26: 720-5.

[14] Sakurai M., Hatou S., Mochizuki H. In vitro effects of fluoroquinolones on corneal epithelial cells and keratocytes. Atarashii Ganka.2006; 23: 1209-12.

[15] Watanabe R., Nakazawa T., Yokokura S. et al. Fluoroquinolone antibacterial eye drops: effects on normal human corneal epithelium, stroma, and endothelium. Clinical Ophthalmology. 2010; 4: 1181-7.

[16] Johnson P. J. Acute and chronic liver disease. Metabolic and Clinical Aspects. W. J. Marshall, S. K. Bangert, eds.Clinical Biochemistry. Churchill livigstone. 1995; 237-56.

[17] Oum B., Kim N., Lee J., Park Y. Effects of fluoroquinolone eye solutions without preservatives on human corneal epithelial cells in vitro. Ophthalmic Res. 2014; 51 (4): 216-23.

[18] Sturgill M. G., Lambert G. H. Xenobiotic induced hepatotoxicity: mechanisms of liver injury and methods of monitoring hepatic function. Clinical Chemistry. 1997; 43 (8): 1512-26.

[19] Tweedale A. C. Uses of «Good Laboratory Practices» by regulated industry and agencies, and the safety of bisphenol A. J. Epidemiol. Community Health. 2011; 65 (6): 475-76.

[20] Zimmerman H. J. Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver, 2nd ed. Philadelphia: Lippincott Williams and Wilkins; 1999.

RIGHTS & PERMISSIONS

Aleksandrova O.I., Okolov I.N., Takhtaev Y.V., Khorolskaya J.I., Hintuba T.S., Blinova M.I.